More drug studies and trials on the way! - CLL Support

CLL Support

22,499 members38,648 posts

More drug studies and trials on the way!

AussieNeil profile image
AussieNeilAdministrator
2 Replies

Good to see the search for improved CLL treatments continues:

1) A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

clinicaltrials.gov/ct2/show...

This is a study evaluating the efficacy, safety, and pharmacodynamics of GS-9973 in subjects with chronic lymphocytic leukemia (CLL), etc.

See also Dr Jeff Sharman's post about this trial at:

cll-nhl.com/2013/04/new-stu...

2) Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (includes CLL and SLL)

Purpose: To determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab

clinicaltrials.gov/show/NCT...

Neil

Written by
AussieNeil profile image
AussieNeil
Administrator
To view profiles and participate in discussions please or .
Read more about...
2 Replies
HAIRBEAR_UK profile image
HAIRBEAR_UKFounder Admin

Thanks Neil, there does seem to be a lot going on. Dr Sharman's blog is really helping to translate the new work and approaches in an understandable way. The landscape is changing we are fortunate to have someone so able to convey thoughts and map this for us.

Your post reminds me of words spoken at recent group meetings by clinical researchers. It is going to become increasingly important to have a consultant with a special interest in CLL on your team able to navigate the growing number of clinical trials available at research hospitals.

Dave3579 profile image
Dave3579

I have never met Dr Sharman, but have the highest regard for him based on the amount of comitment he makes to building a bridge between the patient and the medical world he is a part of through his blogs. he goes into great detail on every aspect of CLL and to have someone who is highly placed in the treatment and design of treatments who reaches out and explain in a clear way to CLLers. I like his candid comments and also the fact he holds out hope to the frightened sufferer that good things are coming. His blog is a must read

You may also like...

Novel Bruton’s Tyrosine Kinase (BTK) inhibitor, ONO-4059 enters UK CLL clinical trial

for the treatment of B-cell malignancies. A Phase I Study in CLL patients of ONO-4059...

Encouraging phase 1 trial results for GLPG5201, a CAR T-cell therapy

in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT)....

Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL

complete responses (CRs) in patients with relapsed/refractory CLL. Results showed that the...

Good end to a bad year... My MRD Results are in!

2, 2020 Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With...

BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies

rate (ORR; phase 2). In 121 efficacy evaluable patients with CLL or SLL treated with a previous...